Clinical lymphoma, myeloma & leukemia

01 21 October 2026

DOI 10.1016/j.clml.2026.10.017

GPRC5D-directed antibodies in multiple myeloma: new agents and frontline strategies from IMS 2026

Open DOI

Changnian Li, Siyuan Cui

02 19 October 2026

DOI 10.1016/j.clml.2026.10.014

Consolidation with hyper-CVAD or VP plus dasatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Randomized Controlled Trial

Open DOI

Xiaoyan Zheng, Ruimin Liu, Juan Ren et al.

03 15 October 2026

DOI 10.1016/j.clml.2026.10.012

Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients

Open DOI

Yi Zhang, Hu Zhou, Junling Zhuang et al.

04 14 October 2026

DOI 10.1016/j.clml.2026.10.010

How Many Lines of Therapy Do Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receive in Routine Clinical Practice in the United States? Real World Evidence from the Targeted Therapy Era

Open DOI

Deborah M. Stephens, Moshe Yair Levy, Naleen Raj Bhandari et al.

05 13 October 2026

DOI 10.1016/j.clml.2026.10.011

FcRH5-targeted therapy in multiple myeloma: evolving clinical strategies and resistance from IMS 2026

Open DOI

Changnian Li, Jingjing Pan

06 12 October 2026

DOI 10.1016/j.clml.2026.10.009

Health-related quality of life with mosunetuzumab plus polatuzumab vedotin in R/R LBCL: Phase 3 SUNMO trial

Open DOI

Won-Seog Kim, Huilai Zhang, Dai Maruyama et al.

07 12 October 2026

DOI 10.1016/j.clml.2026.10.008

Favorable safety and efficacy of duvelisib maintenance after autologous stem cell transplant in peripheral T-cell lymphomas

Open DOI

Hunter Cochran, Ningying Wu, Raya Saba et al.

08 12 October 2026

DOI 10.1016/j.clml.2026.10.006

Real-world experience of using next-generation-sequencing in Multiple Myeloma diagnostics in the UK National Health Service.

Open DOI

Sina A Beer, Elisa Senaca, Giuseppe Bertuglia et al.

09 11 October 2026

DOI 10.1016/j.clml.2026.10.007

Patient-Reported Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab plus Gemcitabine and Oxaliplatin in STARGLO

Open DOI

Gareth P. Gregory, Jeremy S. Abramson, Huiqiang Huang et al.

10 7 October 2026

DOI 10.1016/j.clml.2026.10.005

A Real-World Experience with First-Line RTOG 0227 (Methotrexate, Temozolomide, and Rituximab) Induction for Primary CNS Lymphoma

Open DOI

James J. Fradin, Ramsha Ahmed, Precious Anyanwu et al.